

Update on Avian Influenza

by **Tanya Melillo Fenech MD MSc**
 Principle Medical Officer at Infectious Disease Prevention and Control Unit
 Department of Health Promotion and Disease Prevention

The cumulative number of confirmed cases of human avian influenza since the beginning of the year is 34 cases with 26 deaths. The HPAI subtype H5N1 is unprecedented since there are no records of an epizootic having lasted so long a time and having covered such a wide geographical area in such a short period of time. Up till the end of May this year, 12 countries/territories have notified the recurrence of HPAI H5N1 following its previous eradication, thus indicating that the virus is continuing to circulate. These are the Republic of Korea, Hong Kong (SARPRC), India, Iran, Israel, Japan, Laos, Switzerland, Thailand, Turkey, Ukraine and the United Kingdom (wild birds).

First EU pre-pandemic vaccine
 Last May, GSK's new vaccine Prepandrix was the first pre-pandemic vaccine to obtain a centralised

marketing authorisation. It is formulated with a novel adjuvant system designed to achieve high immune response to a low dose of antigen which is long lasting and active against a broad range of H5N1 strains. The current age indication is 18-60 years. During clinical trials it was found to be well tolerated and showed cross protection.

Scientists publishing in Nature call for diversification of antiviral stockpiles

The potential impact of pandemic influenza makes effective measures to limit the spread and morbidity of virus infection a public health priority. Antiviral drugs are seen as essential requirements for control of initial influenza outbreaks caused by a new virus, and in pre-pandemic plans there is a heavy reliance on drug stockpiles.

The principal target for these drugs is a virus surface glycoprotein, neuraminidase-N1, which facilitates the release of the virus and thus the spread of infection. The presence of N1 neuraminidase on both avian H5N1 and human seasonal influenza A subtype H1N1, shows that both virus sub-types have the same mechanism of resistance to oseltamivir. This data adds weight to the hypothesis that because the molecular structure of zanamivir is a minimal modification of the natural sialic acid substrate, use of zanamivir should minimize the viability of any drug resistant mutations at the enzyme active site, and thus reduce the chances for development of resistance. Due to these findings, scientists recommend the diversification of pandemic stockpile with both types of neuraminidases. [3]



CRESTOR® ...
(rosuvastatin)
THE MOST EFFECTIVE STATIN FOR LOWERING LDL-C 1-8

AstraZeneca  **Lowers LDL-C | Raises HD L-C | Reduces Triglycerides** **CRESTOR®**

Approved prescribing information for CRESTOR. Refer to the full Summary of Product Characteristics before prescribing. **Presentation:** Film coated tablets containing 5mg, 10mg, 20mg or 40mg of rosuvastatin. Indications: For patients symptomatic for cholesterol and other cardiovascular risk factors. **Contraindications:** CRESTOR is contraindicated for patients with known hypersensitivity to rosuvastatin or any of its excipients, active liver disease or abnormal liver function tests, pregnancy, breastfeeding, severe renal impairment or severe hepatic impairment. **Warnings and precautions:** CRESTOR should be used with caution in patients with moderate to severe renal impairment. **Adverse effects:** CRESTOR should be used with caution in patients with moderate to severe renal impairment. **Legal Category:** POM. **Marketing Authorisation Number (UK):** PL 03070/01. **Marketing Authorisation Holder:** AstraZeneca UK Limited. **Address:** AstraZeneca UK Limited, 100 Parkway, Welwyn Garden City, Herts AL9 1QB, UK. **Telephone:** 01438 744333. **Website:** www.astrazeneca.co.uk. **© AstraZeneca 2008.**